Day: March 23, 2026

New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasisAdditional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting. Presentations include new Rhapsido® (remibrutinib) data highlighting changes in daily itch and hives severity scores at week 1 in patients with chronic spontaneous urticaria (CSU), an indirect comparison on Cosentyx® (secukinumab) safety and flare prevention for patients with hidradenitis...

HONG KONG, March 23, 2026 (GLOBE NEWSWIRE) — Willis, a WTW business (NASDAQ: WTW), today announced it has partnered with Circle Asia to launch a new art insurance facility designed specifically for individual collectors and art galleries in Asia. The facility is the first of its kind in Asia, combining specialist arts insurance expertise from Willis and Circle’s digital platform to deliver a seamless and cost-effective way to insure fine art, jewellery and specie collections. Fine art insurance has traditionally required minimum value thresholds or minimum premium commitments from clients. This new facility offers a significantly lower entry premium, giving collectors and galleries easier access to comprehensive coverage through a single, streamlined solution that meets the evolving needs of Asia’s growing art market. Key benefits...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma (“DLBCL”) in China. The first patient received the first dose on March 20, 2026. DLBCL is the most common form of aggressive non-Hodgkin lymphoma (“NHL”) worldwide, accounting for approximately 40% of all NHL cases in China.1  In 2022, approximately 81,000 new cases of NHL are estimated to have been diagnosed in China.2 Bruton’s tyrosine kinase (“BTK”) is considered a validated target for drugs that aim to treat certain hematological cancers. HMPL-760 is a highly...